. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Clin Lung Cancer. 2018 Aug 22;19(6):e893–e900. doi: 10.1016/j.cllc.2018.08.008

Table 3.

Clinical and Laboratory Risk Factors for Development of Immune-related Adverse Events

	irAE, n (%)
Risk Factor	Yes	No	P Value
All patients	27 (30)	64 (70)
Histologic type (nonsquamous, n = 58)	16 (28)	42 (72)	1.00^a
Previous TRT or chest wall RT (n = 28)	8 (29)	20 (71)	.806^a
RT after ICI	8 (53)	7(47)	.059^b
Smoking history			1.00^b
Current/former smoker	24 (30)	57 (70)
Nonsmoker	3 (30)	7 (70.00)
Gender			.260^a
Male	14 (36)	25 (64)
Female	13 (25)	39 (75)
Inflammatory biomarkers			.804^a
ALI ≥ 18	13 (31)	20 (69)	.260^a
NLR ≥ 5	15 (30)	35 (70)	.939^a
PLR ≥ 237	12 (26)	34 (74)	.449^a
KRAS mutation (n = 26)	4(15)	22 (85)	.059^a
TP53 mutation (n = 37)	7(19)	30 (81)	.063^a

Abbreviations: ALI =advanced lung cancer inflammation index; ICI immune checkpoint inhibitor; irAE = immune-related adverse event; NLR = neutrophil/lymphocyte= ratio; PLR platelet/lymphocyte ratio; RT = radiotherapy; TRT thoracic RT.

Association between categorical variables compared using χ² test.

Association between categorical variables compared using Fisher’s exact test.